- Home
- NVNO vs LPCN Comparison
NVNO vs LPCN Comparison
Compare NVNO & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNO
- LPCN
- Stock Information
- Founded
- NVNO 1987
- LPCN 1997
- Country
- NVNO United States
- LPCN United States
- Employees
- NVNO N/A
- LPCN N/A
- Industry
- NVNO Medical/Dental Instruments
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- NVNO Health Care
- LPCN Health Care
- Exchange
- NVNO Nasdaq
- LPCN Nasdaq
- Market Cap
- NVNO 16.7M
- LPCN 13.8M
- IPO Year
- NVNO N/A
- LPCN N/A
- Fundamental
- Price
- NVNO $0.35
- LPCN $3.18
- Analyst Decision
- NVNO
- LPCN Strong Buy
- Analyst Count
- NVNO 0
- LPCN 1
- Target Price
- NVNO N/A
- LPCN $7.00
- AVG Volume (30 Days)
- NVNO 827.4K
- LPCN 54.7K
- Earning Date
- NVNO 10-31-2025
- LPCN 11-06-2025
- Dividend Yield
- NVNO N/A
- LPCN N/A
- EPS Growth
- NVNO N/A
- LPCN N/A
- EPS
- NVNO N/A
- LPCN N/A
- Revenue
- NVNO N/A
- LPCN $4,322,693.00
- Revenue This Year
- NVNO N/A
- LPCN N/A
- Revenue Next Year
- NVNO N/A
- LPCN N/A
- P/E Ratio
- NVNO N/A
- LPCN N/A
- Revenue Growth
- NVNO N/A
- LPCN N/A
- 52 Week Low
- NVNO $0.30
- LPCN $2.52
- 52 Week High
- NVNO $5.62
- LPCN $5.50
- Technical
- Relative Strength Index (RSI)
- NVNO 22.10
- LPCN 61.21
- Support Level
- NVNO $0.30
- LPCN $3.07
- Resistance Level
- NVNO $0.35
- LPCN $3.32
- Average True Range (ATR)
- NVNO 0.05
- LPCN 0.20
- MACD
- NVNO -0.02
- LPCN 0.06
- Stochastic Oscillator
- NVNO 10.37
- LPCN 65.82
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.